Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma
暂无分享,去创建一个
D. Cao | Dong Ke | Hui Liu | Xiaohong Liu | Xiaokang Ke | Ximing Xu
[1] Z. Pan,et al. The effect of marital status on the survival of patients with multiple myeloma , 2022, Hematology.
[2] L. Zhai,et al. The impact of surgery on long-term survival of patients with primary intestinal non-Hodgkin lymphomas based on SEER database , 2021, Scientific Reports.
[3] Junhui Xu,et al. Influence of Severe Gastrointestinal Complications in Primary Gastrointestinal Diffuse Large B-Cell Lymphoma , 2021, Cancer management and research.
[4] Pio Zeppa,et al. Non-Hodgkin Lymphoma. , 2020, Monographs in clinical cytology.
[5] P. Liu,et al. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. , 2019, The oncologist.
[6] Chang-ming Huang,et al. Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study , 2019, BMC Cancer.
[7] K. Izutsu,et al. Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients , 2019, International journal of hematology.
[8] Ben Van Calster,et al. Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. , 2018, European urology.
[9] J. Chavez,et al. Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment , 2018, Cancer control : journal of the Moffitt Cancer Center.
[10] T. Yeh,et al. The role of surgical management in primary small bowel lymphoma: A single-center experience. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[11] J. Chandler,et al. Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality. , 2017, Anticancer research.
[12] M. Russell,et al. Primary Gastrointestinal Non-Hodgkin’s Lymphoma of the Small and Large Intestines: a Systematic Review , 2016, Journal of Gastrointestinal Surgery.
[13] Hua He,et al. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites. , 2016, Blood cells, molecules & diseases.
[14] J. Byrd,et al. Diffuse Large B-Cell Lymphoma Version 1.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] O. Ayyıldız,et al. Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology , 2014, Contemporary oncology.
[16] J. Castillo,et al. Sites of extranodal involvement are prognostic in patients with diffuse large B‐cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database , 2014, American journal of hematology.
[17] J. Huh,et al. Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems , 2013, Journal of Korean medical science.
[18] T. Habermann,et al. Bowel perforation in intestinal lymphoma: incidence and clinical features. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Guangyao Wu,et al. Primary gastrointestinal lymphoma. , 2011, World journal of gastroenterology.
[20] E. Matano,et al. Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. , 2010, World journal of gastroenterology.
[21] A. Ng,et al. Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.
[22] N. Schmitz,et al. Conservative Management of Gastric Lymphoma: the Treatment Option of Choice , 2004, Leukemia & lymphoma.
[23] B. Christensen,et al. Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases , 2004, British journal of haematology.
[24] K. Young,et al. Diffuse large B-cell lymphoma. , 2018, Pathology.